DYADIC INTERNATIONAL INC (DYAI) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 3.88M USD | Liabilities, Current |
| Cash and equivalents | 1.43M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 1.30M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $3.88M | $1.43M | (m) | $1.30M | (m) | (m) |
| 2026-03-31 | (m) | $3.18M | $4.25M | (m) | $996.46K | (m) | (m) |
| 2025-12-31 | (m) | $3.69M | $4.62M | (m) | $1.09M | (m) | (m) |
| 2025-09-30 | (m) | $4.05M | $5.83M | (m) | $916.57K | (m) | (m) |
| 2025-06-30 | (m) | $3.66M | $2.14M | (m) | $715.32K | (m) | (m) |
| 2025-03-31 | (m) | $1.96M | $5.06M | (m) | $221.72K | (m) | (m) |
| 2024-12-31 | (m) | $2.45M | $6.51M | (m) | $237.03K | (m) | (m) |
| 2024-09-30 | (m) | $2.08M | $5.92M | (m) | $352.93K | (m) | (m) |
| 2024-06-30 | (m) | $1.95M | $6.13M | (m) | $249.81K | (m) | (m) |
| 2024-03-31 | (m) | $2.26M | $10.57M | (m) | $246.14K | (m) | (m) |
| 2023-12-31 | (m) | $2.25M | $6.52M | (m) | $466.16K | (m) | (m) |
| 2023-09-30 | (m) | $1.46M | $7.40M | (m) | $417.88K | (m) | (m) |
| 2023-06-30 | (m) | $2.00M | $5.84M | (m) | $767.60K | (m) | (m) |
| 2023-03-31 | (m) | $1.88M | $6.37M | (m) | $754.10K | (m) | (m) |
| 2022-12-31 | (m) | $2.45M | $5.79M | (m) | $330.00K | (m) | (m) |
| 2022-09-30 | (m) | $2.39M | $6.74M | (m) | $235.37K | (m) | (m) |
| 2022-06-30 | (m) | $3.40M | $9.48M | (m) | $1.15M | (m) | (m) |
| 2022-03-31 | (m) | $1.83B | $12.42B | (m) | $528.15M | (m) | (m) |
| 2021-12-31 | (m) | $2.56M | $15.75M | (m) | $277.83K | (m) | (m) |
| 2021-09-30 | (m) | $1.96M | $13.66M | (m) | $179.63K | (m) | (m) |
| 2021-06-30 | (m) | $3.29M | $14.02M | (m) | $291.44K | (m) | (m) |
| 2021-03-31 | (m) | $2.59M | $13.06M | (m) | $384.96K | (m) | (m) |
| 2020-12-31 | (m) | $1.63M | $20.64M | (m) | $294.20K | (m) | (m) |
| 2020-09-30 | (m) | $1.75M | $21.86M | (m) | $806.85K | (m) | (m) |
| 2020-06-30 | (m) | $1.64M | $11.78M | (m) | $564.67K | (m) | (m) |
| 2020-03-31 | (m) | $1.14M | $4.70M | (m) | $518.60K | (m) | (m) |
| 2019-12-31 | (m) | $1.59M | $4.82M | (m) | $558.53K | (m) | (m) |
| 2019-09-30 | (m) | $1.28M | $4.66M | (m) | $418.94K | (m) | (m) |
| 2019-06-30 | (m) | $1.45M | $4.78M | (m) | $504.51K | (m) | (m) |
| 2019-03-31 | (m) | $1.27M | $3.98M | (m) | $425.95K | (m) | (m) |
| 2018-12-31 | (m) | $849.64K | $2.39M | (m) | $318.74K | (m) | (m) |
| 2017-12-31 | (m) | $768.89K | $5.79M | (m) | $271.03K | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |